

ASX:NRT
NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

450 M

Board of Directors

Mr John O'Connor
Chairman
Non-Executive Director

Mr Bryce Carmine
Deputy Chairman
Non-Executive Director

Dr James Garner
Chief Executive Officer
Managing Director

Mr Ian Phillips MNZM
Non-Executive Director

Mr Iain Ross
Non-Executive Director

Mr Steven Coffey
Non-Executive Director

MARKET RELEASE

31 October 2016

INVESTOR PRESENTATION

Sydney, 31st October 2016 – Australian oncology-focused biotechnology company Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to release an investor presentation concerning its in-licensing of a phase II ready molecule (GDC-0084) from Genentech for treatment of brain cancer (Glioblastoma).

[ENDS]

Media and Investor Relations	Investor Relations (US)
Glen Zurcher E: glen.zurcher@irdepartment.com.au T: +61 420 249 299	Robert Kennedy E: robert.kennedy@novogen.com T: +1 212 519 9832 / +1 646 662 3574

About the GDC-0084 development candidate

GDC-0084 is a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is distinguished from other molecules in the class by its ability to penetrate the blood-brain barrier. The molecule was developed by Genentech, who completed a phase I study in recurrent glioblastoma patients, and was licensed to Novogen in October 2016. A phase II clinical trial is slated to begin in 2017.

About Novogen Limited

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of four development candidates, diversified across three distinct technologies, with the potential to yield first-in-class and best-in-class agents across a range of oncology indications.

The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. Three further molecules have been developed in-house from two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) to treat ovarian cancer and a range of solid tumours. Cantrixil, the most advanced of these, is slated to enter clinical trials in late 2016, while Anisina and Trilexium are in preclinical development.

For more information, please visit: www.novogen.com



Novogen Limited

Investor Presentation

In-licensing of phase II ready molecule (GDC-0084)
from Genentech for treatment of brain cancer (Glioblastoma)

31st October 2016

Forward-Looking Statements


This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

Novogen now has a diversified portfolio and is positioned for growth



- **Focus on unmet need:** pipeline of novel therapies, targeting oncology patients, poorly served by existing treatment options
- **Building a sustainable model:** leveraging oncology expertise, developing commercially attractive, in-house and external assets
- **Diversified portfolio:**
 - Multiple assets in various stages of development – from pre-clinical through to phase II-ready
 - Across technologies / development platforms
- **Strong management and board:** lean team of internationally-experienced pharma executives
- **Financially sound:** listed on ASX and NASDAQ, with cash runway
- **News flow:** substantial flow of value-driving milestones over 12-18 months

Novogen is listed on ASX and NASDAQ (via ADRs) and is well-funded for current operations



Market Capitalisation*	A\$ 41 million
Listing	ASX: NRT NASDAQ: NVGN (1:25 ratio)
Average Daily Volume	ASX: ~570,000 /day NASDAQ: ~50,000 ADRs /day
Shares on Issue*	450 million (40% US, 60% Australia)
Outstanding Options / Warrants*	74 million
Cash at Bank** A\$ 33.5 million	

In-licensing of GDC-0084, a promising phase II-ready, well-differentiated drug candidate for the treatment of advanced brain cancer




- GDC-0084 has been in-licensed from Genentech
- Being developed to treat the most common form of primary brain cancer, Glioblastoma Multiforme (GBM)
- Pan-PI3 Kinase inhibitor with some mTOR activity
- Sound rationale for inhibitors of PI3 Kinase as a target for treating GBM: 80-90% of GBM cases have disordered PI3 Kinase
- Designed to cross the blood-brain barrier: a critical success factor for GBM therapies, and not true of other drug candidates
- Clinical data suggestive of activity in a very treatment-resistant Phase I clinical trial population; safety profile consistent with other agents in the class

GDC-0084: transaction deal terms



- Exclusive worldwide development and commercialisation agreement for all uses
- US \$5M upfront, payable at time of contract signing
- Performance-related consideration linked to regulatory and commercial outcomes
- Royalty payments as a percentage of net sales, in-line with industry benchmarks
- Novogen assumes full responsibility for development, commercialisation and maintenance of intellectual property

GDC-0084 has successfully completed a phase I study which established dose and safety profile



Phase I Study

- 47 patients enrolled at 4 centres (MD Anderson, UCLA, Dana-Farber, and Vall d'Hebron)
- Patients were grade 3 or 4 gliomas with at least one (and in most cases, several) lines of prior therapy

- 45mg established as Maximally Tolerated Dose (MTD) for phase II study
- Pharmacokinetic profile consistent with daily dosing
- Safety profile consistent with other PI3K inhibitors, with hyperglycemia and mucositis / stomatitis the most common adverse events
- Promising signals of pharmacodynamic response on FDG-PET, an exploratory radiological marker

Strong strategic rationale for in-licensing GDC-0084

Novogen's strategy includes augmentation of our pipeline through prudent in-licensing

- GDC-0084 is highly complementary to existing pipeline
- Validated mechanism (1x commercial product) and clinical data
- Strengthens Novogen's position as an innovative oncology company


GDC-0084 is an attractive opportunity, phase II-ready and with a validated mechanism

- Designed by Genentech, specifically to address brain cancer which has >\$1b market potential
- Completed phase I studies and ready to commence phase II
- Potential to improve survival for advanced brain cancer that with current standard of care has expected survival of only 12 - 15 months from time of diagnosis
- Strong intellectual property protection


Novogen is ready and able to execute on the GDC-0084 program

- Experienced management team, with int'l big pharma background
- Strong scientific networks, including in glioblastoma through Glioblast acquisition; key thought leaders in neuro-oncology field are highly engaged
- Manufactured drug substance for phase II clinical trial included in transaction
- Strong cash position

Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations



Post transaction pipeline



PI3K Inhibitor Module	Brain-penetrant PI3 Kinase inhibitor with some mTOR activity, targeting PI3K / Akt / mTOR pathway, which is shown to be upregulated in majority of GBM cases and many other tumour types
ATM Platform	First-in-class program targeting cancer-specific tropomyosin isoform in cytoskeletal microfilaments of cancer cells, leading to apoptosis
SBP Platform	First-in-class program based on proprietary isoflavone chemistry effective in killing tumour-initiating cells

Novogen anticipates a rich news flow of value-driving events over the next 12-18 months

Key Milestones		
1Q 2016	Granting of patent for SBP technology	✓
2Q 2016	Granting of patent for ATM technology	✓
3Q 2016	Submission of IND for Cantrixil	✓
4Q 2016	In-licensing of GDC-0084	✓
	Start of phase I trial for Cantrixil	
2017	Submission of IND for Anisina	
	Start of phase II trial for GDC-0084	
	Start of phase I trial for Anisina	



Recap: diversified portfolio, positioned for growth



- **Focus on unmet need:** pipeline of novel therapies, targeting oncology patients, poorly served by existing treatment options
- **Building a sustainable model:** leveraging oncology expertise, developing commercially attractive, in-house and external assets
- **Diversified portfolio:**
 - Multiple assets in various stages of development – from pre-clinical through to phase II-ready
 - Across technologies / development platforms
- **Strong management and board:** lean team of internationally-experienced pharma executives
- **Financially sound:** listed on ASX and NASDAQ, with cash runway
- **News flow:** substantial flow of value-driving milestones over 12-18 months

